InflaRx (IFRX) Long-Term Debt Repayments (2019)
InflaRx's (IFRX) quarterly Long-Term Debt Repayments came in at -$96126.6 in Q4 2019, down 2.63% quarter-over-quarter from -$93665.2 in Q3 2019.
Powered by 
Analysis
InflaRx (IFRX) Long-Term Debt Repayments (2019) Analysis & Trends
InflaRx has disclosed Long-Term Debt Repayments across 1 years of filings, most recently posting -$96126.6 for Q4 2019.
- In Q4 2019, Long-Term Debt Repayments changed N/A year-over-year to -$96126.6; the TTM figure through Dec 2019 stood at -$392761.2 (changed N/A YoY), while the FY2019 annual figure was -$331521.0, changed N/A from the prior year.
- Long-Term Debt Repayments came in at -$96126.6 for Q4 2019 at InflaRx, down from -$93665.2 in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of -$62514.6 in Q1 2019 to a low of -$140454.9 in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | -96,126.55 |
| Sep 30, 2019 | -93,665.16 |
| Jun 30, 2019 | -140,454.89 |
| Mar 31, 2019 | -62,514.59 |